Recurrent Cardiac Tamponade from Multiple Myeloma While Receiving Teclistamab

Alexander Hurtado; Samuel T Luebbe; Emma Kilbane; Toluwalase Awoyemi; Taylor Bronson; Jayesh Mehta; Mohamed M H Al-Kazaz; Adam Y Lin

doi:10.1016/j.jaccas.2024.102763

Recurrent Cardiac Tamponade from Multiple Myeloma While Receiving Teclistamab

JACC Case Rep. 2024 Dec 4;29(23):102763. doi: 10.1016/j.jaccas.2024.102763.

Authors

Alexander Hurtado¹, Samuel T Luebbe¹, Emma Kilbane¹, Toluwalase Awoyemi¹, Taylor Bronson², Jayesh Mehta^{3

4}, Mohamed M H Al-Kazaz^{5

6}, Adam Y Lin^{3

4}

Affiliations

¹ McGaw Medical Center of Northwestern University, Chicago, Illinois, USA.
² Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
³ Division of Hematology and Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
⁴ Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
⁵ Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
⁶ Bluhm Cardiovascular Institute of Northwestern, Chicago, Illinois, USA.

Abstract

Bispecific therapy has changed the treatment paradigm for multiple myeloma. We report a patient with recurrent malignant pericardial effusions with cardiac tamponade and new atrial fibrillation during treatment, suggesting that new or worsening pericardial disease may be a potential cardiovascular adverse effect of bispecific therapy.

Keywords: cardiac tamponade; pericardial effusion; teclistamab.

Publication types

Case Reports